Alto Neuroscience, Inc. (NYSE:ANRO) — Market Cap & Net Worth
Market Cap & Net Worth: Alto Neuroscience, Inc. (ANRO)
Alto Neuroscience, Inc. (NYSE:ANRO) has a market capitalization of $850.38 Million ($850.38 Million) as of August 1, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #9457 globally and #2617 in its home market, demonstrating a 0.82% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alto Neuroscience, Inc.'s stock price $27.07 by its total outstanding shares 35052731 (35.05 Million). Review Alto Neuroscience, Inc. total liabilities to assess the company's total debt and financial obligations.
Alto Neuroscience, Inc. Market Cap History: 2024 to 2026
Alto Neuroscience, Inc.'s market capitalization history from 2024 to 2026. Data shows growth from $146.17 Million to $948.88 Million (23.45% CAGR).
Alto Neuroscience, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alto Neuroscience, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of ANRO by Market Capitalization
Companies near Alto Neuroscience, Inc. in the global market cap rankings as of August 1, 2026.
Key companies related to Alto Neuroscience, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Alto Neuroscience, Inc. Historical Marketcap From 2024 to 2026
Between 2024 and today, Alto Neuroscience, Inc.'s market cap moved from $146.17 Million to $ 948.88 Million, with a yearly change of 23.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $948.88 Million | +52.08% |
| 2025 | $623.94 Million | +326.86% |
| 2024 | $146.17 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 1st, 2026 the market cap of Alto Neuroscience, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $850.38 Million USD |
| MoneyControl | $850.38 Million USD |
| MarketWatch | $850.38 Million USD |
| marketcap.company | $850.38 Million USD |
| Reuters | $850.38 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clini… Read more